Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

Analyst Gena Wang from Barclays maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $50.00.Don't Miss ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

This was corrected on 11/16/2024 at 5:43 PM. An earlier version of this article mistakenly said that RGX-202 uses the AAV9 vector. It uses the AAV8 vector. The article has also been clarified to ...

REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic ...

Cash Runway Guidance: Expected to fund operations into 2026. Regenxbio Inc (NASDAQ:RGNX) is making significant progress in ...